Excellent
Fully Aligned
Patient Risk:
Low
Summary
The AI claim is explicitly and directly supported by multiple sections of the provided FDA label excerpts, including the obesity/weight loss warning, ineffectiveness at replacement-range dosing in euthyroid patients, and the warning about serious/life-threatening toxicity with larger doses, especially with sympathomimetic/anorectic agents.
Category Scores
Accurate Statements
Thyroid hormones including SYNTHROID should not be used to treat obesity or for weight loss.
Supported by 5 Warnings and Precautions: "Thyroid hormones, including SYNTHROID, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss."
Doses in the physiologic replacement (daily hormonal requirements) range are ineffective for weight reduction in euthyroid patients.
Supported by 5 Warnings and Precautions: "In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction."
Larger doses can cause serious or even life-threatening toxicity, particularly when given with sympathomimetic/anorectic agents.
Supported by 5 Warnings and Precautions: "Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects" and further supported by 7.7 Sympathomimetics.
The risk context includes sympathomimetics increasing effects of sympathomimetics or thyroid hormone.
Supported by 7.7 Sympathomimetics: "Concurrent use of sympathomimetics and SYNTHROID may increase the effects of sympathomimetics or thyroid hormone."
Toxicity is consistent with hyperthyroidism and can be severe (including death) with overdosage.
Supported by 6 Adverse Reactions (hyperthyroidism-related adverse reactions including weight loss) and 10 Overdosage: "Cerebral embolism, shock, coma, and death have been reported."
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The claim is a safety-related limitation/warning from the label (obesity/weight loss prohibition and toxicity warning) and does not introduce dosing instructions beyond what the label excerpt states.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement